Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development.

Migliorini D, Mason NJ, Posey AD.

ILAR J. 2019 May 16. pii: ilz009. doi: 10.1093/ilar/ilz009. [Epub ahead of print]

PMID:
31095687
2.

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.

Boydell E, Marinari E, Migliorini D, Dietrich PY, Patrikidou A, Dutoit V.

Cancers (Basel). 2019 Apr 2;11(4). pii: E464. doi: 10.3390/cancers11040464.

3.

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY.

Neuro Oncol. 2019 Feb 12. doi: 10.1093/neuonc/noz040. [Epub ahead of print]

PMID:
30753611
4.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
5.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
6.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

7.

Glycan-directed CAR-T cells.

Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr.

Glycobiology. 2018 Sep 1;28(9):656-669. doi: 10.1093/glycob/cwy008. Review.

PMID:
29370379
8.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY.

Oncoimmunology. 2017 Nov 7;7(2):e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.

9.

Rapidly Growing Pulmonary Metastasis from Anaplastic Meningioma with Lethal Outcome: A Case Report.

Corniola MV, Landis BN, Migliorini D, Lobrinus JA, Ares C, Schaller K, Jägersberg M.

J Neurol Surg Rep. 2017 Oct;78(4):e129-e134. doi: 10.1055/s-0037-1615808. Epub 2017 Dec 28.

10.

CAR T-Cell Therapies in Glioblastoma: A First Look.

Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH.

Clin Cancer Res. 2018 Feb 1;24(3):535-540. doi: 10.1158/1078-0432.CCR-17-2871. Epub 2017 Nov 20.

11.

First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.

Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, McKee T, Dutoit V, Dietrich PY.

Oncoimmunology. 2017 Jun 21;6(8):e1338235. doi: 10.1080/2162402X.2017.1338235. eCollection 2017.

12.

[Brain tumor immunotherapy: Illusion or hope?]

Migliorini D, Dutoit V, Walker PR, Dietrich PY.

Bull Cancer. 2017 May;104(5):476-484. doi: 10.1016/j.bulcan.2017.01.014. Epub 2017 Mar 17. Review. French.

PMID:
28318492
13.

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma.

Migliorini D, Aguiar D, Vargas MI, Lobrinus A, Dietrich PY.

Neurology. 2017 Mar 28;88(13):1291-1293. doi: 10.1212/WNL.0000000000003767. Epub 2017 Feb 24. No abstract available.

14.

Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

Dutoit V, Migliorini D, Dietrich PY, Walker PR.

Front Oncol. 2016 Dec 7;6:256. doi: 10.3389/fonc.2016.00256. eCollection 2016. Review.

15.

Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?

Migliorini D, Fertani S, Dietrich PY.

CNS Oncol. 2016 Oct;5(4):199-201. doi: 10.2217/cns-2016-0019. Epub 2016 Sep 12.

16.

[Immunotherapy for brain tumors: obstacles and perspectives].

Migliorini D, Dietrich PY.

Rev Med Suisse. 2016 Apr 27;12(516):828-31. French.

PMID:
27281940
17.

[Multidisciplinar approach to the management of gliomas].

Moura B, Migliorini D, Bourhis J, Daniel R, Levivier M, Hottinger AF.

Rev Med Suisse. 2016 Apr 27;12(516):821-5. French.

PMID:
27281939
18.

Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.

Migliorini D, Haller S, Merkler D, Pugliesi-Rinaldi A, Koka A, Schaller K, Leemann B, Dietrich PY.

CNS Oncol. 2015;4(6):387-92. doi: 10.2217/cns.15.22. Epub 2015 Oct 26. Review.

19.

Immunotherapy of Brain Tumors.

Dutoit V, Migliorini D, Walker PR, Dietrich PY.

Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4. Review.

PMID:
26376741
20.

The CD40/CD40L axis in glioma progression and therapy.

Walker PR, Migliorini D.

Neuro Oncol. 2015 Nov;17(11):1428-30. doi: 10.1093/neuonc/nov138. Epub 2015 Jul 22. No abstract available.

Supplemental Content

Loading ...
Support Center